PDIA1
All Product Categories
-
PDIA1 Related Products (4)
Related Products (4)
-
PACMA 31
0 ImagesPACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC50 of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues. PACMA 31 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
(E/Z)-E64FC26
0 Images(E/Z)-E64FC26 is a mixture of the stereoisomers E-E64FC26 and Z-E64FC26, in which E-E64FC26 is the active component and acts as a potent PDI inhibitor. The IC50 values of E64FC26 (E-E64FC26) for PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6 are 0.6, 4.8, 33.1, 12.1, and 5.7 μM, respectively. By inhibiting PDI, (E/Z)-E64FC26 causes massive intracellular accumulation of misfolded polyubiquitinated proteins, thereby triggering strong endoplasmic reticulum stress and oxidative stress responses, which in turn induce apoptosis. (E/Z)-E64FC26 is used in research on multiple myeloma, ovarian cancer, and breast cancer.
-
PDIA1/A3-IN-1
0 ImagesCat. No.: HY-187198PDIA1/A3-IN-1 is a PDIA1 and PDIA3 inhibitor, with an IC50 value of 5.30 μM against PDIA1 and an IC50 value of 9.33 μM against PDIA3. PDIA1/A3-IN-1 can be used in research related to prostate cancer, breast cancer, glioblastoma, and cervical cancer.
-
PROTAC PDIA1 degrader 1
0 ImagesCat. No.: HY-178118CAS No.: 3024292-21-2PROTAC PDIA1 degrader 1 is a PDIA1 PROTAC degrader with a DC50 of 29.71 μM. PROTAC PDIA1 degrader 1 induces proteasome-dependent PDIA1 degradation via recruiting E3 ligase, ubiquitination and proteasomal degradation processes. PROTAC PDIA1 degrader 1 exhibits anticancer activity against breast cancer and epidermoid carcinoma. PROTAC PDIA1 degrader 1 can be used for the research of breast cancer and epidermoid carcinoma.
